A Phase 1 interventional study of Caffeine Tablet and Omeprazole capsule in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effect of LOXO-305 on single oral dose of caffeine cytochrome P450 1A2 (CYP1A2) substrate, S-warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate) when administered as multiple doses by collecting the blood samples and conducting the blood tests to measure how much LOXO-305 is in the bloodstream and how the body handles and eliminates LOXO-305 in adult healthy participants. The study will also evaluate the safety and tolerability of LOXO-305. The study will be conducted in two periods. Participants will stay in this study for up to 67 days, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 milligrams (mg) caffeine tablet, 40 mg omeprazole capsule, and 10 mg warfarin tablet as a single dose of probe drug cocktail, along with 10 mg vitamin K tablet on Day 1.
Drug: Caffeine Tablet · Drug: Omeprazole capsule · Drug: Warfarin tablet
Participants received oral dose of 200 mg Pirtobrutinib once daily (QD) from Day 6 to Day 19. On Day 15, Pirtobrutinib was co-administered with 200 mg caffeine tablet, 40 mg omeprazole capsule, and 10 mg warfarin tablet as a single dose of probe drug cocktail, along with 10 mg vitamin K tablet. There was a 5-day washout period between the probe drug cocktail on Day 1 (Period 1) and the first dose of Pirtobrutinib on Day 6 (Period 2).
Drug: Caffeine Tablet · Drug: Omeprazole capsule · Drug: Warfarin tablet · Drug: Pirtobrutinib
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Also known as: LOXO-305, LY3527727
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine
Area under the concentration time curve (AUC) from hour 0 to 24 hours post-dose (AUC0-24) of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Paraxanthine
AUC0-24 of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Omeprazole
AUC0-24 of Omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Warfarin
AUC(0-24) of Warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Pirtobrutinib
AUC0-24 of Pirtobrutinib was reported.
Time frame: Period 2, Day 15 (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post dose)
Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Caffeine
AUC from hour 0 to the last measurable concentration (AUC0-t) of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Paraxanthine
AUC0-t of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Omeprazole
AUC0-t of Omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Warfarin
AUC0-t of Warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Pirtobrutinib
AUC0-t of Pirtobrutinib was reported.
Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Caffeine
AUC from hour 0 extrapolated to infinity (AUC0-inf) of Caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Paraxanthine
AUC0-inf of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Omeprazole
AUC0-inf of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Warfarin
AUC0-inf of Warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Percentage Extrapolation for AUC0-inf (%AUCextrap): Caffeine
AUC0-inf (%AUCextrap) of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Percentage Extrapolation for AUC0-inf (%AUCextrap): Paraxanthine
AUC0-inf (%AUCextrap) of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Percentage Extrapolation for AUC0-inf (%AUCextrap): Omeprazole
%AUCextrap of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Percentage Extrapolation for AUC0-inf (%AUCextrap): Warfarin
%AUCextrap of Warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Apparent Systemic Clearance (CL/F): Caffeine
CL/F for caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Apparent Systemic Clearance (CL/F): Omeprazole
CL/F of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Apparent Systemic Clearance (CL/F): Warfarin
CL/F of warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Apparent Systemic Clearance (CL/F): Pirtobrutinib
CL/F of Pirtobrutinib was reported.
Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Maximum Observed Plasma Concentration (Cmax): Caffeine
Cmax of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Maximum Observed Plasma Concentration (Cmax): Paraxanthine
Cmax of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Maximum Observed Plasma Concentration (Cmax): Omeprazole
Cmax of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Maximum Observed Plasma Concentration (Cmax): Warfarin
Cmax of warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Maximum Observed Plasma Concentration (Cmax): Pirtobrutinib
Cmax of Pirtobrutinib was reported.
Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Time to Maximum Observed Plasma Concentration (Tmax): Caffeine
Tmax of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Time to Maximum Observed Plasma Concentration (Tmax): Paraxanthine
Tmax of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Time to Maximum Observed Plasma Concentration (Tmax): Omeprazole
Tmax of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Time to Maximum Observed Plasma Concentration (Tmax): Warfarin
Tmax of warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Time to Maximum Observed Plasma Concentration (Tmax): Pirtobrutinib
Tmax of Pirtobrutinib was reported.
Time frame: Period 2, Day 15 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours postdose)
Apparent Terminal Elimination Rate Constant (λZ): Caffeine
λZ of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Apparent Terminal Elimination Rate Constant (λZ): Paraxanthine
λZ of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Apparent Terminal Elimination Rate Constant (λZ): Omeprazole
λZ of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Apparent Terminal Elimination Rate Constant (λZ): Warfarin
λZ of warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Apparent Volume of Distribution at Terminal Phase (Vz/F): Caffeine
Vz/F of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Apparent Volume of Distribution at Terminal Phase (Vz/F): Omeprazole
Vz/F of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Apparent Volume of Distribution at Terminal Phase (Vz/F): Warfarin
Vz/F of Warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Metabolite to Parent Drug AUC Ratio (MRAUC): AUC Ratio of Paraxanthine to Caffeine
AUC Ratio of paraxanthine (Metabolite) to caffeine (Parent drug) was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Mean Residence Time (MRT): Caffeine
MRT of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Mean Residence Time (MRT): Paraxanthine
MRT of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Mean Residence Time (MRT): Omeprazole
MRT of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Mean Residence Time (MRT): Warfarin
MRT of warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
Apparent Terminal Elimination Half-Life (t1/2): Caffeine
t1/2 of caffeine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Apparent Terminal Elimination Half-Life (t1/2): Paraxanthine
t1/2 of Paraxanthine was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose)
Apparent Terminal Elimination Half-Life (t1/2): Omeprazole
t1/2 of omeprazole was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours postdose)
Apparent Terminal Elimination Half-Life (t1/2): Warfarin
t1/2 of warfarin was reported.
Time frame: Period 1, Day 1 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose); Period 2, Day 15 (Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose)
| Milestone | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Started | 16 | 0 |
| Received at least 1 dose of study drug | 16 | 0 |
| Completed | 16 | 0 |
| Not completed | 0 | 0 |
| Milestone | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Started | 0 | 16 |
| Received at least 1 dose of study drug | 0 | 16 |
| Completed | 0 | 16 |
| Not completed | 0 | 0 |
Area under the concentration time curve (AUC) from hour 0 to 24 hours post-dose (AUC0-24) of caffeine was reported.
| hour*nanogram per milliliter (h*ng/mL) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Caffeine | 39100 ± 31.8 | 37400 ± 31.8 |
AUC0-24 of Paraxanthine was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Paraxanthine | 20600 ± 12.1 | 18600 ± 17.7 |
AUC0-24 of Omeprazole was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Omeprazole | 2000 ± 100.9 | 3120 ± 61.6 |
AUC(0-24) of Warfarin was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Warfarin | 7320 ± 19.7 | 7880 ± 18.3 |
AUC0-24 of Pirtobrutinib was reported.
| h*ng/mL | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to 24 Hours Post-Dose (AUC0-24): Pirtobrutinib | 119000 ± 24.4 |
AUC from hour 0 to the last measurable concentration (AUC0-t) of caffeine was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Caffeine | 39100 ± 31.8 | 37400 ± 31.7 |
AUC0-t of Paraxanthine was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration-time Curve (AUC), From Hour 0 to the Last Measurable Concentration (AUC0-t): Paraxanthine | 20600 ± 12.1 | 19400 ± 14.0 |
AUC0-t of Omeprazole was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Omeprazole | 1990 ± 101.0 | 3110 ± 61.7 |
AUC0-t of Warfarin was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Warfarin | 17300 ± 19.1 | 19200 ± 20.0 |
AUC0-t of Pirtobrutinib was reported.
| h*ng/mL | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Pirtobrutinib | 119000 ± 24.4 |
AUC from hour 0 extrapolated to infinity (AUC0-inf) of Caffeine was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Caffeine | 42600 ± 39.7 | 40000 ± 37.5 |
AUC0-inf of Paraxanthine was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Paraxanthine | 23100 ± 10.1 | 20300 ± 17.4 |
AUC0-inf of omeprazole was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Omeprazole | 2000 ± 101.0 | 3120 ± 61.6 |
AUC0-inf of Warfarin was reported.
| h*ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) From Hour 0 Extrapolated to Infinity (AUC0-inf): Warfarin | 20100 ± 21.1 | 22400 ± 21.9 |
AUC0-inf (%AUCextrap) of caffeine was reported.
| percentage of AUCextrap | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Percentage Extrapolation for AUC0-inf (%AUCextrap): Caffeine | 5.20 ± 130.6 | 4.17 ± 149.3 |
AUC0-inf (%AUCextrap) of Paraxanthine was reported.
| percentage of AUCextrap | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Percentage Extrapolation for AUC0-inf (%AUCextrap): Paraxanthine | 12.0 ± 58.3 | 7.45 ± 63.6 |
%AUCextrap of omeprazole was reported.
| percentage of AUCextrap | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Percentage Extrapolation for AUC0-inf (%AUCextrap): Omeprazole | 0.421 ± 84.3 | 0.302 ± 97.8 |
%AUCextrap of Warfarin was reported.
| percentage of AUCextrap | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Percentage Extrapolation for AUC0-inf (%AUCextrap): Warfarin | 13.1 ± 33.5 | 13.4 ± 32.7 |
CL/F for caffeine was reported.
| Liter per hour (L/h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Systemic Clearance (CL/F): Caffeine | 4.70 ± 39.7 | 5.00 ± 37.5 |
CL/F of omeprazole was reported.
| L/h | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Systemic Clearance (CL/F): Omeprazole | 20.0 ± 101.0 | 12.8 ± 61.6 |
CL/F of warfarin was reported.
| L/h | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Systemic Clearance (CL/F): Warfarin | 0.497 ± 21.1 | 0.447 ± 21.9 |
CL/F of Pirtobrutinib was reported.
| L/h | Pirtobrutinib 200 mg QD + Probe Drug Cocktail |
|---|---|
| Apparent Systemic Clearance (CL/F): Pirtobrutinib | 1.68 ± 24.4 |
Cmax of caffeine was reported.
| ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax): Caffeine | 5060 ± 17.6 | 4990 ± 14.5 |
Cmax of Paraxanthine was reported.
| ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax): Paraxanthine | 1200 ± 14.3 | 1150 ± 14.6 |
Cmax of omeprazole was reported.
| ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax): Omeprazole | 901 ± 58.0 | 1350 ± 42.3 |
Cmax of warfarin was reported.
| ng/mL | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax): Warfarin | 585 ± 26.1 | 595 ± 25.2 |
Cmax of Pirtobrutinib was reported.
| ng/mL | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|
| Maximum Observed Plasma Concentration (Cmax): Pirtobrutinib | 9430 ± 24.6 |
Tmax of caffeine was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax): Caffeine | 0.500 (0.500 to 1.00) | 0.750 (0.500 to 1.00) |
Tmax of Paraxanthine was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax): Paraxanthine | 10.0 (6.00 to 24.0) | 8.01 (6.00 to 12.0) |
Tmax of omeprazole was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax): Omeprazole | 2.00 (1.50 to 4.00) | 2.50 (1.50 to 4.00) |
Tmax of warfarin was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax): Warfarin | 1.50 (0.500 to 3.00) | 1.50 (0.250 to 3.00) |
Tmax of Pirtobrutinib was reported.
| hour (h) | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax): Pirtobrutinib | 2.50 (0.767 to 4.00) |
λZ of caffeine was reported.
| 1/hour (1/h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Rate Constant (λZ): Caffeine | 0.116 ± 37.8 | 0.127 ± 34.6 |
λZ of Paraxanthine was reported.
| 1/hour (1/h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Rate Constant (λZ): Paraxanthine | 0.0966 ± 24.0 | 0.120 ± 21.8 |
λZ of omeprazole was reported.
| 1/hour (1/h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Rate Constant (λZ): Omeprazole | 0.611 ± 48.4 | 0.578 ± 37.2 |
λZ of warfarin was reported.
| 1/hour (1/h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Rate Constant (λZ): Warfarin | 0.0160 ± 17.1 | 0.0165 ± 16.4 |
Vz/F of caffeine was reported.
| Litre (L) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/F): Caffeine | 40.4 ± 16.8 | 39.4 ± 18.1 |
Vz/F of omeprazole was reported.
| Litre (L) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/F): Omeprazole | 32.8 ± 45.7 | 22.2 ± 33.6 |
Vz/F of Warfarin was reported.
| Litre (L) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/F): Warfarin | 31.0 ± 18.4 | 27.1 ± 21.0 |
AUC Ratio of paraxanthine (Metabolite) to caffeine (Parent drug) was reported.
| Ratio | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Metabolite to Parent Drug AUC Ratio (MRAUC): AUC Ratio of Paraxanthine to Caffeine | 0.528 ± 29.1 | 0.518 ± 27.8 |
MRT of caffeine was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Mean Residence Time (MRT): Caffeine | 8.58 ± 35.8 | 8.03 ± 30.9 |
MRT of Paraxanthine was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Mean Residence Time (MRT): Paraxanthine | 12.8 ± 18.3 | 10.9 ± 14.8 |
MRT of omeprazole was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Mean Residence Time (MRT): Omeprazole | 3.22 ± 32.4 | 3.58 ± 20.1 |
MRT of warfarin was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Mean Residence Time (MRT): Warfarin | 56.8 ± 18.9 | 57.9 ± 18.7 |
t1/2 of caffeine was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Half-Life (t1/2): Caffeine | 5.96 ± 37.8 | 5.47 ± 34.6 |
t1/2 of Paraxanthine was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Half-Life (t1/2): Paraxanthine | 7.17 ± 24.0 | 5.79 ± 21.8 |
t1/2 of omeprazole was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Half-Life (t1/2): Omeprazole | 1.13 ± 48.4 | 1.20 ± 37.2 |
t1/2 of warfarin was reported.
| hour (h) | Period 1: Probe Drug Cocktail | Period 2: Pirtobrutinib + Probe Drug Cocktail |
|---|---|---|
| Apparent Terminal Elimination Half-Life (t1/2): Warfarin | 43.2 ± 17.1 | 42.0 ± 16.4 |
Collected over From Baseline up to End of Study i.e. 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Probe Drug Cocktail | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Pirtobrutinib 200 mg QD | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Pirtobrutinib 200 mg QD + Probe Drug Cocktail | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Event | Probe Drug Cocktail | Pirtobrutinib 200 mg QD | Pirtobrutinib 200 mg QD + Probe Drug Cocktail |
|---|---|---|---|
| PetechiaeSkin and subcutaneous tissue disorders | 0/16 | 5/16 | 0/16 |
| CheilitisGastrointestinal disorders | 0/16 | 1/16 | 0/16 |
| Vessel puncture site painGeneral disorders | 0/16 | 1/16 | 0/16 |
| Seasonal allergyImmune system disorders | 1/16 | 0/16 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 | 0/16 | 0/16 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/16 | 0/16 | 1/16 |
| DizzinessNervous system disorders | 1/16 | 0/16 | 0/16 |
| HeadacheNervous system disorders | 0/16 | 1/16 | 0/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/16 | 1/16 | 0/16 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/16 | 1/16 | 0/16 |
All participants who received at least one dose of the study drug.
| Age, Continuous(years) | Overall Study Participants |
|---|---|
| Mean | 39.1 ± 9.46 |
| Sex: Female, Male(Participants) | Overall Study Participants |
|---|---|
| Female | 4 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study Participants |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall Study Participants |
|---|---|
| United States | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Apr 2021, 3 months.
Results were first posted in Mar 2025, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib